4.7 Article

Microglia, Amyloid, and Glucose Metabolism in Parkinson's Disease with and without Dementia

期刊

NEUROPSYCHOPHARMACOLOGY
卷 38, 期 6, 页码 938-949

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2012.255

关键词

amyloid; microglia; Parkinson's disease; Parkinson's disease dementia; glucose metabolism

资金

  1. Medical Research Council
  2. Medical Research Council, UK
  3. Acadia Pharmaceuticals Inc
  4. Amsterdam Molecular Therapeuctics (AMT) BV
  5. AstraZeneca
  6. BiogeIdec
  7. NeuroNova AB
  8. Eli Lilly and Company
  9. Medtronic Inc
  10. Shire Pharmaceuticals Inc
  11. Synosia Therapeutics AG
  12. GlaxoSmith Kline
  13. UBC Biosciences Inc
  14. Veralis (RD) limited
  15. Genentech Inc
  16. Navidea
  17. UCB
  18. Britannia
  19. GSK
  20. Abbott pharmaceuticals
  21. Abbott
  22. Boehringer-Ingelheim
  23. GE Healthcare
  24. Bayer Healthcare
  25. Lundbeck
  26. Parkinson's research, UK
  27. Alzheimers Research UK [ART-PG2005-3] Funding Source: researchfish
  28. Medical Research Council [G1100809, G84/6523, G0900891, MC_U120036861, G1100810] Funding Source: researchfish
  29. MRC [G0900891, G1100810, MC_U120036861, G1100809, G84/6523] Funding Source: UKRI

向作者/读者索取更多资源

[C-11](R)PK11195-PET measures upregulation of translocator protein, which is associated with microglial activation, [C-11]PIB-PET is a marker of amyloid, while [F-18]FDG-PET measures cerebral glucose metabolism (rCMRGlc). We hypothesize that microglial activation is an early event in the Parkinson's disease (PD) spectrum and is independent of the amyloid pathology. The aim of this study is to evaluate in vivo the relationship between microglial activation, amyloid deposition, and glucose metabolism in Parkinson's disease dementia (PDD) and PD subjects without dementia. Here, we evaluated 11 PDD subjects, 8 PD subjects without dementia, and 24 control subjects. Subjects underwent T1 and T2 MRI, [C-11](R)PK11195, [F-18]FDG, and [C-11]PIB PET scans. Parametric maps of [C-11](R)PK11195 binding potential, rCMRGlc, and [C-11]PIB uptake were interrogated using region of interest and SPM (statistical parametric mapping) analysis. The PDD patients showed a significant increase of microglial activation in anterior and posterior cingulate, striatum, frontal, temporal, parietal, and occipital cortical regions compared with the controls. The PD subjects also showed a statistically significant increase in microglial activation in temporal, parietal, and occipital regions. [C-11]PIB uptake was marginally increased in PDD and PD. There was a significant reduction in glucose metabolism in PDD and PD. We have also demonstrated pixel-by-pixel correlation between mini-mental state examination (MMSE) score and microglial activation, and MMSE score and rCMRGlc. In conclusion, we have demonstrated that cortical microglial activation and reduced glucose metabolism can be detected early on in this disease spectrum. Significant microglial activation may be a factor in driving the disease process in PDD. Given this, agents that affect microglial activation could have an influence on disease progression. Neuropsychopharmacology (2013) 38, 938-949; doi:10.1038/npp.2012.255; published online 16 January 2013

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据